Cure8 research brief
If you have PSC-IBD or care for someone who does, this study suggests the gut microbiota and its ability to make secondary bile acids may help drive inflammation and colorectal dysplasia risk.
Targeting microbial bile-acid functions could become a future prevention strategy rather than simply giving bile acids directly.
Clinicians managing PSC-IBD, researchers studying microbiome–bile acid interactions and colorectal neoplasia, and patients with PSC-associated ulcerative colitis interested in emerging research directions.
PSC-UC showed greater microscopic inflammation and a right-sided excess of dysplasia in the clinical cohort.
In the mouse model, communities lacking 7α-dehydroxylation capacity had near-absent deoxycholic and lithocholic acids and drove right-predominant colitis and multifocal dysplasia; germ-free status protected mice and transfer of live microbiota from affected mice reinstated disease.
Sterile-filtered stool was not sufficient, suggesting live microbes were required. Restoring BA-transforming microbial functions (rather than simply giving secondary bile acids) is proposed as a translational strategy; direct deoxycholic acid replacement caused hepatotoxicity in germ-free DKO mice.
This brief is grounded in the article abstract as provided by PubMed.
Findings come from a combination of human surveillance data and mouse-model experiments described in the article abstract. The study is translational and preclinical; potential therapies would require careful testing because direct secondary bile-acid repletion produced liver toxicity in the model. The abstract-level summary does not replace full peer review of study details.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Competing interests: RBS has consulted for and received grant support from Janssen, Vedanta, BiomX, Biomica, SERES, Ferring and Immuny X. TS is an advisor for AbbVie, Johnson and Johnson Innovative Medicine and Nxera. MA has received speaker fees from Ipsen.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Tertiary lymphoid organs form in IBD and may influence disease course; understanding how lymphatic S1PR1 controls TLOs could reveal new targets to modify intestinal inflammation without broad immunosuppression.
The study describes a new oral, colon‑targeted delivery system that improved outcomes in a mouse model of ulcerative colitis and shifted immune and microbiome markers—research that could inform future therapies focused...
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
